Bicara Therapeutics Inc. Common Stock (BCAX) S-1 IPO registration

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated June 10, 2024, with respect to the consolidated financial statements of Bicara Therapeutics Inc., included herein, and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

Boston, Massachusetts

August 22, 2024